Q2 EPS Forecast for Amicus Therapeutics Reduced by Analyst

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Research analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Amicus Therapeutics in a note issued to investors on Tuesday, June 3rd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' FY2025 earnings at ($0.01) EPS, Q2 2026 earnings at $0.04 EPS, FY2026 earnings at $0.28 EPS, Q1 2027 earnings at $0.07 EPS and FY2027 earnings at $0.43 EPS.

A number of other equities analysts have also recently weighed in on FOLD. UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. The Goldman Sachs Group decreased their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, Wells Fargo & Company decreased their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Price Performance

Shares of FOLD traded up $0.20 during trading hours on Friday, reaching $6.16. 5,145,551 shares of the company's stock traded hands, compared to its average volume of 2,935,286. The stock has a market cap of $1.90 billion, a PE ratio of -34.22, a price-to-earnings-growth ratio of 1.51 and a beta of 0.54. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The firm's 50 day simple moving average is $6.61 and its 200-day simple moving average is $8.45. Amicus Therapeutics has a 12 month low of $5.81 and a 12 month high of $12.65.

Hedge Funds Weigh In On Amicus Therapeutics

A number of large investors have recently bought and sold shares of FOLD. Summit Investment Advisors Inc. increased its stake in shares of Amicus Therapeutics by 4.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock valued at $289,000 after buying an additional 1,280 shares during the period. Diversified Trust Co increased its stake in shares of Amicus Therapeutics by 2.2% during the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock valued at $682,000 after buying an additional 1,784 shares during the period. Tempus Wealth Planning LLC increased its stake in shares of Amicus Therapeutics by 7.2% during the first quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock valued at $241,000 after buying an additional 1,990 shares during the period. Xponance Inc. increased its stake in shares of Amicus Therapeutics by 11.9% during the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 2,249 shares during the period. Finally, Covestor Ltd increased its stake in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 2,312 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.